Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by toinv261on Jun 18, 2014 11:35am

272 Views

Post# 22671076

Investor Village post

Hi folks.

The following summary was posted on IV. Great for rvx-208 and us!!!

Re: Lower HDL, ApoA-I levels may signal glycemic deterioration in type 2 diabetes

the researchers wrote. “The results are thus consistent with the emerging concept that HDL biology may play a direct role in the development and progression of type 2 diabetes.”

Looks really good for us going forward on the diabetes end as well.

F6

Apologies if this has already been posted but I think it is key.

Other subjects

Pfizer deal with Cellectis posted by Jkj I think.
It looks like a CVR to me based on how Don described but I think there may be a very important distinction. When Don described a CVR he essentially said the acquisitor with it's agreement essentially would buy RVX with the up front payment, payouts at successful milestones and then royalites it goes to market. Therefore it would no longer be listed on the TSX.

In the Pfizer/Cellectis deal I was surprised by the low $80,000,000 up front payment and then when I read the deal they are not buying Cellectis. They are paying (along with milestone payments and potential royalites, etc) for the exclusive rites for Cellectis to develop treatments for 15 diseases selected by Pfizer. Cellectis can also develop 9 other treatments selected by themselves.

Then Pfizer bought approximately 10% of the Cellectis shares.

I guess the point I'm making is that if Don would sell all of RVX (as opposed to 10%) then the upfront payment should be much higher than $80,000,000.

Please straighten me out if I'm wrong.

Lack of Communications
I've been thinking about this again and why communications is so poor from RVX. The reasons could be as follows;

They have nothing to say - I don't believe that because they have many good things to say even if just based on telling about the relevance and ideas from the conferences they have attended.
They don't believe in communications - I don't believe that because someone, I think Sanfran, has indicated they were fairly high communicaters in the past.
Don doesn't feel communications is relevant at this time - This is my guess. Why? Because, as another poster stated, this is a signal that he is heavily involved in negotiating a big deal such as a CVR and therefore broad communications are not neccessary AND he must be extremely careful to not let information slip out that would see him end up being sued or fined.